Korean J Hematol 2004; 39(2):
Published online June 30, 2004
© The Korean Society of Hematology
양덕환, 김여경, 변정래, 조상희, 정익주, 이제중, 김형준, 김종관, 김동환, 손상균, 이원섭, 도영록, 송홍석, 박준성, 김효철
전남대학교 의과대학 내과학교실,
조혈계질환 유전체연구센터,
경북대학교 의과대학 내과학교실,
경상대학교 의과대학 내과학교실,
계명대학교 의과대학 내과학교실,
아주대학교 의과대학 내과학교실
BACKGROUND:
In combination with standard-dose CHOP (cyclophosphamide, vincristine, adriamycin, and prednisolone), the addition of rituximab produces a better clinical response in the treatment of aggressive B-cell non-Hodgkin´s lymphoma (NHL) than CHOP alone.
METHODS :
Thirty-four patients with previously untreated diffuse large B-cell NHL received at least three or four cycles of rituximab 375 mg/m2 or 500 mg per dose on day 1 of each cycle in combination with CHOP chemotherapy.
RESULTS :
The median age of patients were 61.5 years (range, 28-83 years). After the end of therapy, twenty-five patients (73.5%) experienced a complete response, four patients (11.8 %) had a partial response, and two patients (5.9%) were classified as having progressive disease. The median follow-up duration was 9.4 months (range, 0.2-19.5 months) and 1-year overall survival and progression free survival was 84.8+/-8.7% and 80.3+/-9.4%, respectively. Two patients (5.9%) experienced fever, myalgia, and skin eruption due to rituximab. Neutropenia of grade 3 or 4 occurred in thirty-one patients (91.2%).
CONCLUSION :
The benefits of rituximab in combination with CHOP chemotherapy include high response rates and good tolerance. However, further prospective, randomized studies are needed to draw definitive conclusions.
Keywords CHOP, Rituximab, B-cell lymphoma
Korean J Hematol 2004; 39(2): 59-65
Published online June 30, 2004
Copyright © The Korean Society of Hematology.
양덕환, 김여경, 변정래, 조상희, 정익주, 이제중, 김형준, 김종관, 김동환, 손상균, 이원섭, 도영록, 송홍석, 박준성, 김효철
전남대학교 의과대학 내과학교실,
조혈계질환 유전체연구센터,
경북대학교 의과대학 내과학교실,
경상대학교 의과대학 내과학교실,
계명대학교 의과대학 내과학교실,
아주대학교 의과대학 내과학교실
Deok Hwan Yang, Je Jung Lee, Yeo Kyeoung Kim, Jeong Rae Byun, Sang Hee Cho, Ik Joo Chung, Hyeoung Joon Kim, Jong Gwang Kim, Dong Hwan Kim, Sang Kyung Sohn, Won Sup Lee, Young Rok Do, Hong Suk Song, Joon Seong Park, Hugh Chul Kim
Department of Hematology, Oncology, Chonnam National University Medical School, Gwangju, Korea,
Genome Research Center for Hematopoietic Diseases, Chonnam National Hwasun Hospital, Hwasun, Jeonnam, Korea,
Kyungpook National University Hospital, Daegu, Korea,
Gyeongsang National University Hospital, Jinju, Korea,
Keimyung University School of Medicine, Korea,
Ajou University School of Medicine, Suwon, Korea.
BACKGROUND:
In combination with standard-dose CHOP (cyclophosphamide, vincristine, adriamycin, and prednisolone), the addition of rituximab produces a better clinical response in the treatment of aggressive B-cell non-Hodgkin´s lymphoma (NHL) than CHOP alone.
METHODS :
Thirty-four patients with previously untreated diffuse large B-cell NHL received at least three or four cycles of rituximab 375 mg/m2 or 500 mg per dose on day 1 of each cycle in combination with CHOP chemotherapy.
RESULTS :
The median age of patients were 61.5 years (range, 28-83 years). After the end of therapy, twenty-five patients (73.5%) experienced a complete response, four patients (11.8 %) had a partial response, and two patients (5.9%) were classified as having progressive disease. The median follow-up duration was 9.4 months (range, 0.2-19.5 months) and 1-year overall survival and progression free survival was 84.8+/-8.7% and 80.3+/-9.4%, respectively. Two patients (5.9%) experienced fever, myalgia, and skin eruption due to rituximab. Neutropenia of grade 3 or 4 occurred in thirty-one patients (91.2%).
CONCLUSION :
The benefits of rituximab in combination with CHOP chemotherapy include high response rates and good tolerance. However, further prospective, randomized studies are needed to draw definitive conclusions.
Keywords: CHOP, Rituximab, B-cell lymphoma
Geundoo Jang, Dok Hyun Yoon, Shin Kim, Dae Ho Lee, Sang-wook Lee, Jooryung Huh, and Cheolwon Suh
Korean J Hematol 2011; 46(2): 103-110Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50